Perfuze® Announces First Stroke Patient Enrolled in the MARRS Pivotal Clinical Trial for the Millipede System

GALWAY, Ireland--(BUSINESS WIRE)--Perfuze, a private medical device company dedicated to developing pioneering technology to treat acute ischemic stroke, announced commencement of enrollment in its pivotal MARRS (Millipede AspiRation for Revascularization in Stroke) clinical study. MARRS is a multi-center trial to evaluate the performance of the Millipede System. The first patient was enrolled at Stony Brook University Hospital in Stony Brook, NY. “I am delighted to begin enrollment in the MARR